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Abstract
Background: Gastric and esophageal cancers are among the most lethal human malignancies. Their epidemiology
is geographically diverse. This study compares the survival of gastric and esophageal cancer patients among
several ethnic groups including Chinese, South Asians, Iranians and Others in British Columbia (BC), Canada.
Methods: Data were obtained from the population-based BC Cancer Registry for patients diagnosed with invasive
esophageal and gastric cancer between 1984 and 2006. The ethnicity of patients was estimated according to their
names and categorized as Chinese, South Asian, Iranian or Other. Cox proportional hazards regression analysis was
used to estimate the effect of ethnicity adjusted for patient sex and age, disease histology, tumor location, disease
stage and treatment.
Results: The survival of gastric cancer patients was significantly different among ethnic groups. Chinese patients
showed better survival compared to others in univariate and multivariate analysis. The survival of esophageal
cancer patients was significantly different among ethnic groups when the data was analyzed by a univariate test
(p = 0.029), but not in the Cox multivariate model adjusted for other patient and prognostic factors.
Conclusions: Ethnicity may represent underlying genetic factors. Such factors could influence host-tumor
interactions by altering the tumor’s etiology and therefore its chance of spreading. Alternatively, genetic factors
may determine response to treatments. Finally, ethnicity may represent non-genetic factors that affect survival.
Differences in survival by ethnicity support the importance of ethnicity as a prognostic factor, and may provide
clues for the future identification of genetic or lifestyle factors that underlie these observations.
Background
Gastric and esophageal cancers are among the most
lethal human malignancies. Worldwide, gastric cancer is
the fourth most common cancer, but the second most
common cause of death from cancer [1]. Esophageal
cancer is the eighth most common cancer, but the sixth
most common cause of cancer death [1]. The epidemiol-
ogy of these cancers is geographically diverse. Incidence
rates for gastric cancer vary from 3.4 per 100,000
among women in North America to 26.9 per 100,000
among men in Asia. The 5-year survival is usually about
20% [2]; however, countries with higher incidence rates
of gastric cancer generally have better survival rates
than countries with lower incidence [3]. Incidence rates
for esophageal cancer range from 5-10 per 100,000 in
North America to more than 100 per 100,000 in Eastern
Iran near the Caspian Sea [4]. The differences between
populations reflect environmental and lifestyle (includ-
ing healthcare) factors, as well as genetic profiles [5].
In order to investigate risk associated with genetic
characteristics of a population (ie. ethnicity) and to
reduce or eliminate environmental confounding, it is
preferable to conduct a study in a single geographic area
with a heterogenous population rather than to conduct
international comparisons [5]. British Columbia (BC),
Canada, has a multi-ethnic population. Based on 2006
census data, about one in every four of the 4,428,400
British Columbians (24.8%) belongs to a visible minority,
representing about one million people in the province.
Visible minority is a category that includes persons who
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are non-Caucasian in race or non-white in colour and
who do not report being Aboriginal http://www.statcan.
gc.ca/concepts/definitions/minority01-minorite01a-eng.
htm. Of these, approximately 75% were born outside
Canada, and about 60% immigrated to BC from 1991 to
2006 [6]. That indicates about 676,000 immigrants and
297,000 non-immigrants in BC belonged to a visible
minority group in 2006 [6]. Chinese was the largest
group, accounting for 40% of all visible minorities in the
province, followed by South Asians (26%) [6]. Iranians
represent a relatively small but growing percentage of
the BC population (0.5%, or 19,000 people) in 2001 [7],
although they originate from a geographic region with
the world’s highest incidence of gastric and esophageal
cancers [8,9]. This study compares survival of gastric
and esophageal cancer patients among Chinese, South
Asian and Iranian and other ethnic groups in BC.
Methods
This study received approval from the Research Ethics
Board at the BC Cancer Agency (BCCA). The study
uses historical patient records and, accordingly, patients
were not re-contacted. Cancer incidence and survival
data for invasive primary esophageal and gastric cancers
were obtained from the population-based BC Cancer
Registry (BCCR) for all BC patients diagnosed between
1984 and 2006. The BCCR receives national information
regarding the vital status of patients and is updated
accordingly. The topology and histology of cases were
coded according to the International Classification of
Diseases for Oncology, Third Edition (ICD-O) [10] for
greater coherence with registry information recorded
during the entire study time period. The topography for
esophageal cancers was then grouped into four cate-
gories: esophagus upper third (ICD-O codes C15.0-
C15.3), esophagus middle third (ICD-O codes C15.4),
esophagus lower third and overlapping lesions (ICD-O
codes C15.5), and esophagus unknown (ICD-O codes
C15.8 and C15.9). The topography for gastric cancer
was grouped into three categories: proximal third (car-
dia) in the gastroesophageal junction or upper third of
the stomach (ICD-O codes C16.0 and C16.1), distal sto-
mach or lower two thirds of the stomach (ICD-O codes
C16.2-C16.7), and unknown or unspecified/overlapping
lesion (ICD-O codes C16.8 and C16.9). Histological
categories for esophageal cancers were squamous cell
carcinoma (ICD-O codes 8050-8082), adenocarcinoma
(ICD-O codes 8140-8573) and others (mainly ICD-O
codes 8000-8020). Histology for gastric cancer was also
categorized based on the Lauren classification system as
diffuse or intestinal type [11] (diffuse gastric tumors
defined by histology codes 8142, 8145 and 8490) [12].
For both esophageal and gastric cancers, nonepithelial
tumors (ICD-O codes 8800-9759) were excluded.
Primary treatment was categorized as surgery, che-
motherapy and radiotherapy, with only therapeutic (i.e.,
not diagnostic) surgeries being considered as treatment.
Some patients received more than one type of primary
treatment, but other information, including information
about adjuvant therapy and individual hospitals
attended, was not available. Overall survival was the pri-
mary study outcome, and was calculated as the time
between diagnosis and death. Complete follow-up infor-
mation was available for all patients to 31 August 2007.
The ethnicity of patients was determined according to
their names and categorized as Chinese, South Asian or
Iranian. This method for identification of ethnicity was
necessary because the BCCR does not record ethnicity
or place of birth. Two sources were used to generate
surname listings for each of the three ethnic groups:
local telephone directories and the Screening Mammo-
graphy Program of BC (SMPBC; a population-based
screening program serving nearly 50% of the age-eligible
female population in BC) database. The names in local
telephone directories were reviewed manually to identify
Chinese, South Asian and Iranian surnames; this was
done by several members of the research team from
each of the respective ethnic groups. In addition, since
the SMPBC database retains both ‘place of birth’ and
‘ethnic group’ as reported by the client, all surnames
were listed from this source for Chinese women report-
ing ‘Chinese’ as their ethnicity, South Asian women
reporting ‘India’, and Iranian women reporting ‘Iran’.
The same members of the research team reviewed these
surname listings and eliminated names that were not
typically Chinese, South Asian or Iranian, or which were
common to other population groups. This method to
identify ethnicity has been used in a number of other
studies [7,13-16]] and the methodology has been dis-
cussed elsewhere [17-19]. Patients not classified as
belonging to any of these three ethnic groups were cate-
gorized as “Other.” Based on the ethnic distribution of
the BC population, more than 80% of “Other” are Brit-
ish and Western Europeans [20]. British and Western
Europeans could not be separated as a group because
corresponding name lists do not exist.
Univariate comparisons of demographic, tumor and
treatment variables between ethnic groups were per-
formed using Chi-square tests. Survival was calculated
using the Kaplan-Meier method and log-rank tests were
used to compare survival differences among groups. All
analyses were performed separately for non-metastatic
(Stage I-III) and metastatic (Stage IV) disease. Cox pro-
portional hazards regression was used to estimate the
effect of ethnicity adjusted for patient sex, age (less than
55 years, 55-64 years, 65-74 years and 75+ years), date
of diagnosis (1984-1990, 1991-1995, 1996-2000, 2001-
2006), tumor histology (intestinal and diffuse for gastric
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cancer; adenocarcinoma and squamous cell carcinoma
for esophageal cancer), tumor location, disease stage
and primary treatment received (surgery, radiotherapy
and/or chemotherapy). The hazard ratio (HR) was calcu-
lated for each ethnic group and is the ratio of the
hazard rate in each ethnic group compared to the
“Other” group. For each HR, a 95% confidence interval




3136 cases of invasive gastric cancer were diagnosed
during the study period. Descriptive information for the
cases is shown by ethnicity in Table 1. The age and sex
distributions were significantly different among the eth-
nic groups (p < 0.01). A higher proportion of Chinese
and South Asian gastric cancer patients were female as
compared to the other ethnic groups. The average age
at diagnosis was 61.0 years for Iranians, 62.6 years for
Chinese, 61.7 years for South Asians, and 65.4 years for
Other ethnicities. There were significant differences
among the year of diagnosis by ethnicity (p < 0.01).
Tumor location was significantly different among the
ethnic groups (p < 0.01). Tumors in the proximal 1/3 of
the stomach were more common in South Asians and
Other ethnicities as compared to Chinese and Iranians.
Histology based on the Lauren classification was also
significantly different among ethnic groups (p = 0.03).
The diffuse type of gastric cancer was most common
among Chinese compared to the other ethnic groups.
The distribution of stage and proportion with metastatic
disease was not significantly different among the ethnic
groups; however, treatment by surgery and chemother-
apy were significantly different among the ethnic groups.
The Chinese and Iranian groups received surgery more
often than people in the South Asian or Other groups
(p < 0.01), and the South Asian and Iranian groups
received chemotherapy more often than Chinese or
Others (p < 0.01). Among treated groups; 61% of Ira-
nians, 47% of Chinese, 54% of South Asians and 41% of
Others received more than one type of primary
Table 1 Descriptive characteristics for gastric cancer by ethnicity
Iranian Chinese South Asian Other p
Sex (N = 3136) Male 15 (78.9%) 168 (62.2%) 57 (58.8%) 1974 (71.8%) p < 0.001
Female 4 (21.1%) 102 (37.8%) 40 (41.2%) 776 (28.2%)
Age in years (N = 3136) Less than 55 7 (36.8%) 86 (31.9%) 26 (26.8%) 515 (18.7%) p < 0.001
55-64 3 (15.8%) 49 (18.1%) 20 (20.6%) 652 (23.7%)
65-74 7 (36.8%) 65 (24.1%) 35 (36.1%) 884 (32.1%)
75 and More 2 (10.5%) 70 (25.9%) 16 (16.5%) 699 (25.4%)
Years of Diagnosis (N = 3136) 1984-1990 0 (0.0%) 32 (11.9%) 11 (11.3%) 643 (23.4%) p < 0.001
1991-1995 7 (36.8%) 54 (20.0%) 16 (16.5%) 481 (17.5%)
1996-2000 4 (21.1%) 63 (23.3%) 27 (27.8%) 626 (22.8%)
2001-2006 8 (42.1%) 121 (44.8%) 43 (44.3%) 1000 (36.4%)
Tumor Histology - Lauren classification (N = 3136) Intestinal 14 (73.7%) 205 (75.9%) 74 (76.3%) 2188 (79.6%) 0.032
Diffuse 3 (15.8%) 55 (20.4%) 13 (13.4%) 382 (13.9%)
Other 2 (10.5%) 10 (3.7%) 10 (10.3%) 180 (6.5%)
Tumor Location (N = 3136) Proximal 1/3 6 (31.6%) 52 (19.3%) 47 (48.5%) 1302 (47.3%) p < 0.001
Distal 2/3 10 (52.6%) 171 (63.3%) 28 (28.9%) 894 (32.5%)
NES/NOS* 3 (15.8%) 47 (17.4%) 22 (22.7%) 554 (20.1%)
Tumor Stage (N = 2567) I 1 (5.6%) 14 (6.1%) 3 (3.7%) 108 (4.8%) 0.85
II 6 (33.3%) 65 (28.5%) 29 (35.8%) 702 (31.3%)
III 6 (33.3%) 96 (42.1%) 29 (35.8%) 829 (37.0%)
IV 5 (27.8%) 53 (23.2%) 20 (24.7%) 601 (26.8%)
Surgery (N = 3080) Yes 14 (73.7%) 178 (66.7%) 56 (57.7%) 1502 (55.7%) 0.0027
No 5 (26.3%) 89 (33.3%) 41 (42.3%) 1195 (44.3%)
Chemotherapy (N = 3065) Yes 10 (52.6%) 116 (43.6%) 44 (45.4%) 906 (33.8%) p < 0.001
No 9 (47.4%) 150 (56.4%) 53 (54.6%) 1777 (66.2%)
Radiotherapy (N = 3058) Yes 6 (31.6%) 99 (37.1%) 43 (44.3%) 1203 (45.0%) 0.061
No 13 (68.4%) 168 (62.9%) 54 (55.7%) 1472 (55.0%)
* NES not elsewhere specified; NOS not otherwise specified.
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treatment (ie., Surgery+Chemotherapy+Radiotherapy,
Surgery+Chemotherapy, Surgery+Radiotherapy or Che-
motherapy+Radiotherapy). Each type of primary treat-
ment was included as a separate variable in multivariate
models. Iranians had a median survival of 20 months
(95%CI; 10.6-29.4), Chinese had a median survival of
16 months (95%CI; 12.5-19.1), South Asians had a med-
ian survival of 15 months (95%CI; 11.2-18.1) and Others
had a median survival of 10 months (95%CI; 9.4-10.7).
Figure 1 shows survival curves for gastric cancer
patients according to ethnic group. Survival was signifi-
cantly different between ethnic groups (p < 0.01).
Iranians (HR = 0.62, 95%CI; 0.31-0.96), South Asians
(HR = 0.87, 95%CI; 0.59-0.94) and Chinese (HR = 0.77,
95%CI; 0.61-0.81) showed better survival than people in
the Other category. When considered separately by
presence or absence of metastatic disease, statistically
significant differences were only found for non-meta-
static disease (p < 0.01), as shown in Figure 2. South
Asians (HR = 0.72, 95%CI; 0.54-0.97) and Chinese
(HR = 0.64, 95%CI; 0.53-0.76) showed better survival
than the Other category. The survival of Iranians (HR
= 0.50, 95%CI; 0.24-1.04) was also better than people
in the Other category, but the small number of Ira-
nians (and wide confidence interval) does not exclude
the possibility that this is due to chance. Furthermore,
the association between survival and ethnicity was only
significant for patients with non-metastatic disease
who received therapeutic surgery (p < 0.01), as shown
in Figure 3.
In multivariate analyses adjusting for patient factors,
disease factors and treatment, there was an overall sig-
nificant difference among ethnic groups. For individual
ethnic groups, only Chinese had significantly longer sur-
vival than the Other ethnicities, as shown in Table 2.
This survival advantage in Chinese was only seen for
non-metastatic disease (HR = 0.78, 95% CI; 0.64-0.95).
Esophageal cancer
2873 cases of esophageal cancer were diagnosed during
the study period. Descriptive characteristics of these
patients are presented by ethnicity in Table 3. The
majority of South Asians were women whereas the
majority in the other ethnic groups were men (p <
0.01). There was no significant difference in age at diag-
nosis among the ethnic groups, the average age being
73.0 years, 68.0 years, 65.5 years and 68.4 years for Ira-
nians, Chinese, South Asians and Other ethnicities,
respectively. There was no significant difference among
ethnic groups based on date of diagnosis.
Figure 1 Survival of gastric cancer patients by ethnic group.
Figure 2 Survival of gastric cancer patients by ethnic group for
non-metastatic disease.
Figure 3 Survival of gastric cancer patients who received
surgery by ethnic group for non-metastatic disease.
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Tumour location was significantly different among
ethnic groups (p < 0.01). More than half of tumors in
Iranians and Other ethnicities were located lower third
of the esophagus whereas this location was less common
in Chinese and South Asians. Histology was significantly
different among the ethnic groups (p < 0.01), with
Chinese and South Asians having higher proportions of
squamous cell carcinoma compared to Iranians and
Other ethnicities.
There were no significant differences in stage or the
proportion with metastatic disease among ethnic groups.
Treatment received was not different, except for che-
motherapy which had significant differences among the
ethnic groups (p < 0.01), with the Chinese, Iranian and
South Asian patients accessing chemotherapy more
often than Other ethnicities. 15% of Iranians, 45% of
Chinese, 46% of South Asians and 42% of people in the
Other category received more than one type of primary
treatment. Iranians had median survival of 7 months
(95%CI; 2.1-11.9), Chinese had a median survival of 10
months (95%CI; 7.0-12.9), South Asians had a median
survival of 9 months (95%CI; 6.9-11.1) and people in the
Other category had a median survival of 8 months (95%
CI; 7.6-10.6). Figure 4 shows the survival curves for
Table 2 Effect size of ethnicity for overall survival of
gastric cancer patients
Ethnicity N HR 95% CI p
Iranian 16 0.64 0.34 1.18 P = 0.006
Chinese 214 0.76 0.65 0.90
South Asian 72 0.88 0.68 1.14
Other 2038 Reference
Hazard ratio (HR) and 95% confidence interval (CI) from Cox proportional
hazards regression analysis adjusted for patient sex, patient age, year of
diagnosis, tumor histology (Lauren), tumor location, tumor stage and
treatment.
Table 3 Descriptive characteristics for esophageal cancer by ethnicity
Iranian Chinese South Asian Other P
Sex (N = 2873) Male 10 (71.4%) 94 (74.6%) 57 (47.9%) 1821 (69.7%) p < 0.001
Female 4 (28.6%) 32 (25.4%) 62 (52.1%) 793 (30.3%)
Age in years (N = 2873) Less than 55 0 (0.0%) 14 (11.1%) 21 (17.6%) 314 (12.0%) 0.12
55-64 1 (7.1%) 35 (27.8%) 32 (26.9%) 610 (23.3%)
65-74 9 (64.3%) 41 (32.5%) 35 (29.4%) 858 (32.8%)
75 and More 4 (28.6%) 36 (28.6%) 31 (26.1%) 832 (31.8%)
Years of Diagnosis (N = 2873) 1984-1990 3 (21.4%) 16 (12.7%) 22 (18.5%) 486 (18.6%) 0.164
1991-1995 1 (7.1%) 26 (20.6%) 15 (12.6%) 580 (22.2%)
1996-2000 3 (21.4%) 38 (30.2%) 33 (27.7%) 637 (24.4%)
2001-2006 7 (50%) 46 (36.5%) 49 (41.2%) 911 (34.9%)
Tumor Histology (N = 2873) SCC * 5 (35.7%) 103 (81.7%) 81 (68.1%) 1389 (53.1%) p < 0.001
AC ** 7 (50.0%) 19 (15.1%) 27 (22.7%) 1101 (42.1%)
Other 2 (14.3%) 4 (3.2%) 11 (9.2%) 124 (4.8%)
Tumor Location (N = 2873) Upper 1/3 2 (14.3%) 23 (18.3%) 17 (14.3%) 314 (12.0%) p < 0.001
Middle 1/3 1 (7.1%) 45 (35.7%) 34 (28.6%) 605 (23.1%)
Lower 1/3 9 (64.3%) 40 (31.7%) 51 (42.9%) 1383 (52.9%)
NES/NOS*** 2 (14.3%) 18 (14.3%) 17 (14.3%) 312 (12.0%)
Tumor Stage (N = 2594) I 1 (8.3%) 12 (10.3%) 8 (7.6%) 212 (9.0%) 0.84
II 6 (50.0%) 66 (56.9%) 56 (53.3%) 1363 (57.8%)
III 3 (25.0%) 27 (23.3%) 26 (24.8%) 459 (19.4%)
IV 2 (16.7%) 11 (9.5%) 15 (14.3%) 326 (13.8%)
Surgery (N = 2830) Yes 2 (15.4%) 24 (19.2%) 35 (29.9%) 630 (24.5%) 0.23
No 11 (84.6%) 101 (80.8%) 82 (70.1%) 1944 (75.5%)
Chemotherapy (N = 2820) Yes 0 (0.0%) 39 (31.2%) 25 (21.6%) 526 (20.5%) 0.0084
No 13 (100.0%) 86 (68.8%) 91 (78.4%) 2039 (79.5%)
Radiotherapy (N = 2853) Yes 13 (100.0%) 112 (89.6%) 111 (93.3%) 2240 (86.3%) 0.052
No 0 (0.0%) 13 (10.4%) 8 (6.7%) 355 (13.7%)
*SCC squamous cell carcinoma.
**AC adenocarcinoma.
*** NES not elsewhere specified; NOS not otherwise specified.
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esophageal cancer patients by ethnic group (p = 0.029).
In univariate analysis only South Asian (HR = 0.82, 95%
CI; 0.67-1.00) showed slightly better survival comparing
to Other. In multivariate analyses, South Asians showed
better survival compared to the Other ethnicity group in
the individual group comparison, however the overall
difference among ethnic groups was not significant
(Table 4). A significant survival difference only was
observed among ethnic groups for patients with non-
metastatic disease (p = 0.0498), as shown in Figure 5.
Again, South Asians showed better survival compared to
the Other ethnicity group (HR = 0.74, 95%CI; 0.56-0.97)
in the multivariate analysis.
Discussion
An earlier population-based study in BC reported over-
all five-year survival rates of 8.8% for esophageal cancer
and 16.2% for gastric cancer [21]. The current study was
conducted to examine the effect of ethnicity on survival.
The selection of ethnic groups was based on the predo-
minant ethnic groups in the BC population and avail-
ability of ethnicity information. Our results indicate that
patient ethnicity is a prognostic factor for both gastric
and esophageal cancer; however ethnicity is only
an independent prognostic factor for gastric cancer
patients.
Ethnicity may represent biological characteristics of
patients. Genetic variation may be responsible for differ-
ences in tumor-host interactions, such as the micro-
architecture of tumors [22] and the complex process of
metastasis, both of which are influenced by host genetic
polymorphisms [23]. Ethnicity may also determine life-
style and environmental characteristics including cul-
tural, socioeconomic, and religious practices. Such
differences are expected to be less apparent with
increasing generations after immigration. Additionally,
migration itself is one of the determinants of health out-
come, and the “healthy migrant effect” could explain
some of the observed survival difference among ethnic
groups [24]. The difference in patient survival is not
likely to be due to healthcare disparities among minority
groups, as all BC residents receive free healthcare
through the BC Medical Services Plan (MSP). Interest-
ingly, survival was found to be better in minority groups
compared to the BC general population.
Prognostic factors can be classified into three broad
groups: i) tumor-related, ii) host-related, and iii) envir-
onment-related (including healthcare, treatment and
lifestyle) factors [25,26]. Among tumor-related prognos-
tic factors, disease stage is the most important [26] and
often strongly influences the treatment plan. There were
no significant differences in the stage distributions
among ethnic groups; however, survival differences
among ethnic groups were only significant for non-
metastatic (i.e., stage I-III) disease. After adjustment for
other factors (such as stage), the prognostic effect of
ethnicity was significant only for gastric cancer patients.
Location of tumor (i.e., tumor topography) is a poten-
tial determinant of cancer survival. Our observation
Figure 4 Survival of esophageal cancer patients by ethnic
group.
Table 4 Effect size of ethnicity for overall survival of
esophageal cancer patients
Ethnicity N HR 95% CI P
Iranian 10 1.13 0.61 2.12
Chinese 95 0.9 0.72 1.13 0.14
South Asian 81 0.8 0.59 0.98
Other 1947 Reference
Hazard ratio (HR) and 95% confidence interval (CI) from Cox proportional
hazards regression analysis adjusted for patient sex, patient age, year of
diagnosis, tumor histology, tumor location, tumor stage and treatment.
Figure 5 Survival of esophageal cancer patients by ethnic
group for non-metastatic disease.
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indicates significant differences in tumor location among
different ethnic groups. It has been shown previously in
Western countries that gastric cardia tumors are asso-
ciated with worse survival compared to distal gastric
tumors [27-29]. In addition, for studies of esophageal can-
cer, the location of tumors also showed differences in sur-
vival. Tumors in the middle 1/3 of the esophagus show
worse survival in Turkey and Ardabil (Iran) [30,31], but
tumors in the lower 1/3 of the esophagus are reported to
have worse survival in BC and the United States[21,32].
Among host-related prognostic factors, ethnic differ-
ences were found for sex and age in both gastric and
esophageal cancer. Of environment-related factors, treat-
ment is likely the most powerful determinant of survival.
There were significant ethnic differences in the propor-
tions of gastric cancer patients who received surgery
and chemotherapy. The reason for treatment differences
among ethnic groups is not clear in a system where all
patients have equal access to cancer care, but the differ-
ences might be explained by disease factors, other
patient characteristics or patient preferences.
The result for gastric cancer is consistent with several
US studies in which all other ethnic groups had better
survival compared to the non-Hispanic white population
[33], and a Los Angeles study that showed that Asians
with gastric adenocarcinoma had superior outcomes
compared to other ethnic groups [34]. Our study also
confirms the findings of an earlier study in BC that
reported better survival outcomes for gastric cancer
patients with Asian ethnicity compared to the general
population [35]. Our findings are consistent with inter-
national population-based cancer survival data that indi-
cate that the 5-year survival for gastric cancer in China
is higher than in India [36]. A comparison between
registries from Shanghai (China) and Madras (India)
shows that the 5-year relative survival for gastric (20%
versus 7.5%) and esophageal cancer (9.0% versus 6.9%)
is better in Shanghai [37]. These survival rates for both
cancers are also higher than those reported in Iran [38].
It has been suggested that lower quality care and dis-
parities in treatment are major contributors to differ-
ences in survival between minority and non-minority
populations [39]. BC residents have access to publicly-
funded healthcare, and the BC Cancer Agency (BCCA)
has developed province-wide treatment guidelines and
protocols [40].
Strengths and limitations
The main strength of this study is the availability of reli-
able population-based data with details on tumor histol-
ogy and pathology, treatment, disease stage and survival
outcomes. The main limitation of this study is the lack
of self-reported ethnicity information, requiring the use
of a proxy method (i.e., name lists) to assign ethnicity.
The weakness of using name lists as proxy for ethnicity
is greater for women, who may change their surnames
after marriage. Women account for only 30% of gastric
and esophageal cancer cases in BC[21], but the possibi-
lity of misclassification in this subset must be consid-
ered. Based on a Statistics Canada report, visible
minorities in Canada are a relatively young group and
only 29% are older than 45 years, compared with 41% in
the general population that are older than 45 http://
www40.statcan.ca/l01/cst01/demo50a-eng.htm. Gastric
and esophageal cancer is diagnosed at a late age and the
observed survival differences between ethnicities in this
study might be due to age distributions.
Conclusions
Our study investigated ethnicity as a prognostic factor for
gastric and esophageal cancer patients. It has been shown
that for gastric cancer, patient ethnicity is significant and
Chinese patients experience better survival than people
from the Other ethnicity (i.e., non-South-Asian, non-Chi-
nese and non-Iranian) group. Despite the observed survi-
val benefit for gastric cancer patients who are Iranian,
the low number of patients in this ethnic group does not
permit a meaningful interpretation. Our results also indi-
cate that, for esophageal cancer, South Asians have better
survival compared to the Other ethnicity group.
Gastric and esophageal cancers are deadly diseases
that are often diagnosed at a stage when the treatment
options are limited and less effective. Ethnicity may
represent underlying genetic factors. Such factors could
influence host-tumor interactions by altering tumor
etiology and therefore its chance of spreading. Alterna-
tively, genetic factors may determine response to treat-
ments. Finally, ethnicity may represent non-genetic
factors that affect survival. Differences in survival by
ethnicity support the importance of ethnicity as a prog-
nostic factor, and may provide clues for the future iden-
tification of genetic or lifestyle factors that underlie
these observations.
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